Navigation Links
BYDUREON (TM) FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Date:5/6/2010

n the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight-loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. See important safety information below.  Additional information about BYETTA is at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on post-marketing data, BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who have severe kidney problems, and should be used with caution in people who have had a kidney transplant. Patients should talk with their healthcare provider if they have severe problems with their stomach, such as delayed emptying of the stomach (gastroparesis) or problems with digesting food. Severe allergic reactions can happen with BYETTA.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
3. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. AEterna Zentaris Announces Outcome of Managements Strategic Review
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
10. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
11. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
(Date:5/21/2015)... 2015 uBiome, the leading startup ... with PicnicHealth, a healthcare company that collects and ... Inflammatory Bowel Disease (IBD) will receive a complementary ... research kit. Both companies were funded by Y ... For more information on this partnership and how ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... As ... ... as other commercial real estate sectors struggle, investors continue to pour hundreds of millions ... new debt and $30 million in new equity from Prudential Real Estate Investors (PREI), ...
... , SAN DIEGO, July 30 ... plans to develop a DNA-based orthobiologics product portfolio based on ... initially focus on non-union bone fractures for medically-compromised patients, and ... is a rapidly growing segment of the orthopedics market and ...
... PDI, Inc. (Nasdaq: PDII ), a leading provider of ... PDI director Gerald P. Belle has been appointed to the newly-established position ... has been a director of the Company since April 2008. He is ... "Jerry has served as an invaluable board member during his tenure with ...
Cached Biology Technology:Millions Flowing into Medical Real Estate 2Millions Flowing into Medical Real Estate 3Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 2Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 3Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 4Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 5Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 6Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 7Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 8Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 9Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors 10PDI Appoints Gerald P. Belle as Lead Independent Director 2PDI Appoints Gerald P. Belle as Lead Independent Director 3
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the need for costly insulin injections for diabetics, regenerating ... disease by engineering immune cells top a list of ... emerging from the new world of regenerative medicine, according ... Public Library of Science (PLoS) Medicine. , Conducted by ...
... is highly susceptible to mammary tumors, Cornell researchers have found ... (copying) and breast cancer. , The mouse contains a mutation ... and mice that increases the rate of flawed copies of ... a paper published in Nature Genetics online (and upcoming in ...
... novel vascular targeting agent completely prevented the development of ... in a preclinical study, providing early evidence that it ... a common destination for a number of cancers when ... of Texas M. D. Anderson Cancer Center reported in ...
Cached Biology News:Replacing insulin is top-ranked breakthrough foreseen for health in developing world 2Replacing insulin is top-ranked breakthrough foreseen for health in developing world 3Replacing insulin is top-ranked breakthrough foreseen for health in developing world 4Replacing insulin is top-ranked breakthrough foreseen for health in developing world 5Replacing insulin is top-ranked breakthrough foreseen for health in developing world 6Mutant mouse provides insights into breast cancer 2'Trojan Horse' agent halts bone metastasis in mice 2'Trojan Horse' agent halts bone metastasis in mice 3
Apoptosis Detection Systems and Reagents...
... feeding tubes for rodent oral gavage feature ... of perforation and trauma. Plus they are ... and the risk of cross-contamination. ... 20ga Length: ...
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: